I think we may be underestimating the impact of Resverlogix's incredibly weak financial state....

It may be that there are plenty of market players who view 208 as having strong potential....but equally recognize that the company is basically broke at this stage without the ability to advance the program any further. 

And of course potential is just that....its not a sure thing.  What shows promise in a Phase 2 type trial with small patient numbers may not be borne out in a larger phase 3 trial, especially when new drugs/therapies are constantly being added to the mix and thus move the goal posts further down the field.  

One thing I know has been touted during my 5+ years invested here is the patent life.....how long does it go exactly now?  With each passing year the value of that patent life diminishes does it not?